The challenges of using kinase inhibitors for AML treatment
Allogeneic transplant for older AML patients - who, when and how
Drugs vs transplants in acute leukemias
Safety and efficacy of venetoclax plus LDAC in treatment-naive AML patients aged ≥ 65 years
How do targeted treatments for IDH1 and IDH2 mutations work in acute myeloid leukemia (AML)?